Dr Lal PathLabs slips 1.5% after SN Genelab acquisition; Nomura retains 'Buy', TP Rs 2,150

Nomura has retained its 'Buy' call on Dr Lal PathLabs with a target price of Rs 2,150 after the diagnostics company acquired a 70% stake in genomics testing firm SN Genelab for Rs 1.68 billion.Dr Lal PathLabs markshares were trading at Rs 1,930.90, down 1.55% on the NSE at 11:08 am on September 25…